Pennsylvania SB 1186: An Act amending the act of November 21, 2016 (P.L.1318, No.169), known as the Pharmacy Audit Integrity and Transparency Act, in preliminary provisions, further providing for definitions; and, in pharmacy benefits manager contracts, providing for State pharmacy benefits manager.
Status: Referred to Health & Human Services (as of 2026-03-12)
State: Pennsylvania · Session: 2025-2026 · Bill: SB 1186
Sponsors: Lisa Boscola, Amanda Cappelletti, Christine Tartaglione, Cris Dush, David Argall, James Malone, John Kane, Judy Ward, Lindsey Williams, Maria Collett, Nick Pisciottano, Rosemary Brown, Steven Santarsiero, Timothy Kearney
Bill Text
PRINTER'S NO. 1500 THE GENERAL ASSEMBLY OF PENNSYLVANIA SENATE BILL No. 1186 Session of 2026 INTRODUCED BY BOSCOLA, J. WARD, COLLETT, TARTAGLIONE, DUSH, PISCIOTTANO, CAPPELLETTI, ARGALL AND KEARNEY, MARCH 12, 2026 REFERRED TO HEALTH AND HUMAN SERVICES, MARCH 12, 2026 AN ACT Amending the act of November 21, 2016 (P.L.1318, No.169), entitled, as amended, "An act providing for pharmacy audit procedures, for registration of pharmacy benefits managers and auditing entities, for maximum allowable cost transparency, for prescription drugs reimbursed under the PACE and PACENET program and for pharmacy benefit managers contract requirements and prohibited activities; and making related repeals," in preliminary provisions, further providing for definitions; and, in pharmacy benefits manager contracts, providing for State pharmacy benefits manager. The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows: Section 1. The definitions of "specialty drug" and "spread pricing" in section 103 of the act of November 21, 2016 (P.L.1318, No.169), known as the Pharmacy Audit Integrity and Transparency Act, added July 17, 2024 (P.L.852, No.77), are amended to read: Section 103. Definitions. The following words and phrases when used in this act shall have the meanings given to them in this section unless the context clearly indicates otherwise: * * * 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 "Specialty drug." [Either of the following: (1) A prescription drug prescribed to a covered individual with a cost that meets or exceeds the cost of a drug on the specialty tier of Medicare Part D under 42 CFR 423.104(d)(2)(iv) (relating to requirements related to qualified prescription drug coverage) and meets three or more of the following criteria: (i) The drug requires specialized product handling or administration by the dispensing pharmacy. (ii) The drug requires specialized clinical care, including, but not limited to, frequent dosing adjustments to the prescription drug, clinical monitoring or expanded patient service, intensive patient counseling and ongoing clinical support, such as individualized disease or therapy management to support patient outcomes for a covered individual. (iii) The drug is prescribed for a covered individual with a rare medical condition, complex or chronic medical condition or life-threatening medical condition. (iv) The prescription drug has a limited or exclusive distribution and is not typically stocked or dispensed by a retail pharmacy. (2) A prescription drug that is prescribed to a covered individual and that is listed as a specialty drug on the medical assistance fee-for-service specialty pharmacy drug list.] Prescription medication used to treat complex or chronic conditions that requires special handling, provider coordination or patient education and monitoring for which a retail community pharmacy is not reasonably equipped to 20260SB1186PN1500 - 2 - 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 handle, store, provide counseling regarding use and safely distribute. * * * "Spread pricing." A model of prescription drug pricing in which the PBM charges a health benefit plan or health insurer a contracted price for prescription drugs and the contracted price for the prescription drugs [differs from] is more than the amount the PBM directly or indirectly pays the pharmacist or pharmacy for prescription drugs and related pharmacist services. Section 2. The act is amended by adding a section to read: Section 605. State pharmacy benefits manager. (a) Duty of Department of Human Services .-- The Department of Human Services, by July 31, 2026, shall select and enter into a master contract with a single third-party administrator to serve as the State pharmacy benefits manager to administer all pharmacy benefits for Medicaid recipients, including those enrolled in a managed care organization by such date with whom the Department of Human Services contracts for the delivery of Medicaid services. (b) Requirement .-- Each managed care contract entered into or renewed by the Department of Human Services for the delivery of Medicaid services by a managed care organization shall require the managed care organization to contract with and utilize the State pharmacy benefits manager for the purpose of administering all pharmacy benefits for Medicaid recipients enrolled with the managed care organization. (c) Contractor compliance .--The State pharmacy benefits manager shall comply with the provisions of this act unless otherwise prohibited by Federal law. (d) Procurement process.-- 20260SB1186PN1500 - 3 - 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 (1) The Secretary of Human Services must, through a competitive procurement process that is in compliance with paragraph (2) , select a State pharmacy benefits manager to comply with subsection (e). (2) The competitive procurement process shall: (i) accept app
View Pennsylvania SB 1186 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.